572 related articles for article (PubMed ID: 15139068)
41. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
42. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
43. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
von Poblozki A; Dempke W; Schmoll HJ
Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
[TBL] [Abstract][Full Text] [Related]
44. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
[TBL] [Abstract][Full Text] [Related]
45. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
[TBL] [Abstract][Full Text] [Related]
46. "Rescue" agent may circumvent rare but deadly complication from chemotherapy.
Jenks S
J Natl Cancer Inst; 1997 Jun; 89(12):840-1. PubMed ID: 9196247
[No Abstract] [Full Text] [Related]
47. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
Yamada K; Takahashi M; Yoshida M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
[TBL] [Abstract][Full Text] [Related]
48. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis.
Ahmad S; Shen FH; Bleyer WA
Arch Intern Med; 1978 Jul; 138(7):1146-7. PubMed ID: 666479
[TBL] [Abstract][Full Text] [Related]
49. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
50. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
51. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
52. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
53. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
[TBL] [Abstract][Full Text] [Related]
54. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
[TBL] [Abstract][Full Text] [Related]
55. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
[No Abstract] [Full Text] [Related]
56. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
Kickinger W; Ritschl P; Kotz R
Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
[TBL] [Abstract][Full Text] [Related]
57. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
58. [Managing methotrexate toxicity: a case report].
Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ
Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095
[TBL] [Abstract][Full Text] [Related]
59. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
60. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors.
Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R
Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]